度洛西汀和舍曲林治疗癌症后抑郁患者的疗效观察

目的探讨度洛西汀治疗癌症后抑郁患者的临床疗效。方法将50例癌症后抑郁患者随机分为度洛西汀和舍曲林组各25例,观察治疗6周。于治疗前及治疗1周、2周、4周、6周末采用汉密顿抑郁量表（HAMD）和焦虑量表（HAMA）评定疗效,用治疗中出现的症状量表（TESS）评定药物不良反应,根据卡氏功能量表（KPS）进行生活质量评估。结果汉密顿抑郁量和焦虑量表评分显示,与治疗前相比,度洛西汀组治疗1周末起有显著性下降（P〈0.05）,舍曲林组治疗2周末起有显著性下降（P〈0.05）,两组同期比较1、2周末均有显著的区别（P〈0.05）,两组在6周末疗效、生活质量和副反应方面均无显著区别（P〈0.05）。结论度洛西汀治疗癌症后抑郁疗效与舍曲林相当,但起效更快,耐受性好。

Clinical Study on Duloxetine and Sertralin for the Treatment of Depressive Cancer Patients

Objective To study the efficiency and safety of Duloxetine in the treatment of the depressive cancer.Methods 50 depressive cancer patients were randomly assigned into Duloxetine and Sertralin groups（each n=25）for 6 weeks.Clinical effectiveness was assessed with the Hamilton Depression Scale（HAMD）,Hamilton Anxiety Scale（HAMA）,adverse reactions with Treatment Emergent Symptom Scale（TESS）,quality of life with the Karnofsky Scale（KPS）.Results In the Duloxetine and Sertralin group,the scores of the HAMD and HAMA decreased significantly since the end of the 1st or 2st week compared with pre-treatment separatly（P0.05）.However,the tolal scores of HAMD and HAMA in Duloxetine group were significantly lower than that in Sertralin group after 1st and 2st week.No diferences were found in the efficacy rates,improvement of quality of life and adverse reactions between two groups at the end of 6th week,but obvious diferences with pre-treatmen.Conclusion Duloxetine is a safe,effective and rapidly responsive antidepressant to cancer depression compared to Sertralin.